ACOR keeping an eye on the next few days ACOR
keeping an eye on the next few days
High volumes with NEW HIGH OBV
−12.80USD
−65.916MUSD
118.566MUSD
1.234M
About Acorda Therapeutics, Inc.
Sector
CEO
Ronald Cohen
Headquarters
New York
Website
Employees (FY)
122
Founded
1995
ISIN
US00484M7002
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine), and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa, and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in New York, NY.
Buy $ACOR - NRPicks 12 NovAcorda Therapeutics, Inc. a biopharmaceutical company, develops and markets therapies for neurological disorders in the United States. The company markets Ampyra , an oral medication to improve gait in patients with multiple sclerosis (MS).
Buy $ACOR - NRPicks 11 JunAcorda Therapeutics, Inc. a biopharmaceutical company, develops and markets therapies for neurological disorders in the United States. The company markets Ampyra, an oral drug to improve gait in patients with multiple sclerosis; Inbrija for the treatment of OFF periods in Parkinson's disease.
Its
$ACOR (Requested Analysis - I hold no position)@carsonusa5 You know how to read my charts, right?? 🤣 I'm sorry, I'm tired and don't want to do a full analysis... but ONLY ADD AT THE SUPPORT LEVELS (labeled)
ACORThere is no such things as 100% wins. Always proceed with caution and conduct your own analysis.
*Not Financial advice*
Price at low BB and 200 MA level This one should be going as soon as it breaks the downside trend line, this should happen soon as it is trading at low BB level and 200 day MA, almost impossible it goes down.
Sale of Manufacturing Operations and Global Supply AgreementAcorda Therapeutics Announces Agreement for Sale of Manufacturing Operations and Long-Term Global Supply Agreement for INBRIJA®, Corporate Restructuring, and Enters into "At The Market" Offering Agreement
$80 million up-front payment will substantially increase cash balance
Sale, restructuring and
ACORDA POTENTIAL SLEEPING GIANT COMING AWAKEBe ready, I think acorda is going to make a big move soon.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
